Cytokinetics Announces Additional Results From FORTITUDE-ALS to be Presented at the 18th Annual NEALS Meeting
September 26 2019 - 4:00PM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that
additional results from FORTITUDE-ALS
(
Functional
Outcomes in
a
Randomized
Trial
of
Investigational
Treatment
with CK-2127107
to
Understand
Decline
in
Endpoints – in
ALS),
the Phase 2 clinical trial of reldesemtiv in patients
with amyotrophic lateral sclerosis (ALS), will be presented in a
poster session at the 18th Annual Northeast Amyotrophic Lateral
Sclerosis (NEALS) Meeting at the Opal Sands Resort in Clearwater
Beach, FL.
Title: FORTITUDE-ALS: Who
received the most benefit, and translation to real world
eventsPoster Presenter: Jeremy M. Shefner, M.D.,
Ph.D., Lead Investigator of FORTITUDE-ALS, Professor and Chair of
Neurology at Barrow Neurological Institute, and Professor and
Executive Chair of Neurology at the University of Arizona,
PhoenixDate: October 3,
2019Session: Poster Group ATime:
3:45 – 5:45 PMPoster Number: 77
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators and best-in-class muscle
inhibitors as potential treatments for debilitating diseases in
which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is collaborating with Amgen Inc.
(Amgen) to develop omecamtiv mecarbil, a novel cardiac muscle
activator. Omecamtiv mecarbil is the subject of an international
clinical trials program in patients with heart failure including
GALACTIC-HF and METEORIC-HF. Amgen holds an exclusive worldwide
license to develop and commercialize omecamtiv mecarbil with a
sublicense held by Servier for commercialization in Europe and
certain other countries. Cytokinetics is collaborating with
Astellas Pharma Inc. (Astellas) to develop reldesemtiv, a fast
skeletal muscle troponin activator (FSTA) for diseases of
neuromuscular dysfunction, including SMA and ALS. Astellas holds an
exclusive worldwide license to develop and commercialize
reldesemtiv. Licenses held by Amgen and Astellas are subject to
specified co-development and co-commercialization rights of
Cytokinetics. Cytokinetics is also developing CK-274, a novel
cardiac myosin inhibitor that company scientists discovered
independent of its collaborations, for the potential treatment of
hypertrophic cardiomyopathies. Cytokinetics continues its over
20-year history of pioneering innovation in muscle biology and
related pharmacology focused to diseases of muscle dysfunction and
conditions of muscle weakness.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the “Act”). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements and claims
the protection of the Act's Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Cytokinetics’ and its partners’
research and development activities; the Phase 2 clinical study of
reldesemtiv in patients with ALS, including that such results may
support progression of reldesemtiv into a potentially pivotal Phase
3 clinical trial; the potentially beneficial effects of
reldesemtiv; and the properties and potential benefits of
Cytokinetics’ other drug candidates. Such statements are based on
management's current expectations, but actual results may differ
materially due to various risks and uncertainties, including, but
not limited to, potential difficulties or delays in the
development, testing, regulatory approvals for trial commencement,
progression or product sale or manufacturing, or production of
Cytokinetics’ drug candidates that could slow or prevent clinical
development or product approval; Astellas’ decisions with respect
to the design, initiation, conduct, timing and continuation of
development activities for reldesemtiv; Cytokinetics may incur
unanticipated research and development and other costs or be unable
to obtain additional financing necessary to conduct development of
its products; standards of care may change, rendering Cytokinetics’
drug candidates obsolete; competitive products or alternative
therapies may be developed by others for the treatment of
indications Cytokinetics’ drug candidates and potential drug
candidates may target; and risks and uncertainties relating to the
timing and receipt of payments from its partners, including
milestones and royalties on future potential product sales under
Cytokinetics’ collaboration agreements with such partners. For
further information regarding these and other risks related to
Cytokinetics’ business, investors should consult Cytokinetics’
filings with the Securities and Exchange Commission.
Contact:CytokineticsDiane WeiserVice President,
Corporate Communications, Investor Relations(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024